BNGO vs GDTC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BNGO exhibits severe financial distress despite modest revenue growth, as reflected in its Piotroski F-Score of 1/9—indicating weak operational and financial health. The absence of an Altman Z-Score and the company's negative profitability metrics (e.g., -134.36% profit margin, -78.22% ROE) signal deep operational inefficiencies and high risk of insolvency. Although the stock shows a recent technical uptick and strong earnings surprise history, these are overshadowed by deteriorating fundamentals, massive losses, and a 5-year price decline of 100%. The lack of a Graham Number and intrinsic value estimate further underscores the absence of a reliable valuation anchor. Analysts have a target price of $5.50, but this is not supported by current fundamentals and appears speculative.
GDTC exhibits a fragile financial profile characterized by a Piotroski F-Score of 4/9, placing it in the 'stable' but lower-tier health category. While the company maintains strong liquidity (Current Ratio 5.17) and very low debt, these are overshadowed by a catastrophic operating margin of -535.25% and a total lack of profitability. The technical trend is severely bearish (0/100), with the stock price having declined over 63% in the last year and 75% over five years. Despite positive revenue growth, the valuation remains disconnected from fundamentals, trading at a high Price/Sales ratio of 13.74 without a path to earnings.
Compare Another Pair
Related Comparisons
BNGO vs GDTC: Head-to-Head Comparison
This page compares Bionano Genomics, Inc. (BNGO) and CytoMed Therapeutics Limited (GDTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.